Document:

Exhibit 10.01 Share Exchange Agreement

SHARE EXCHANGE AGREEMENT

This Share Exchange Agreement, dated as of May 8th, 2017, (this “Agreement”) by and among Oculus, Inc., Nevada corporation (“OCLL”) and One Media Enterprises Limited, a corporation duly formed and existing under the laws of England and Wales (“ONEM”), and the Shareholders of ONEM (the “ONEM Shareholders”). For purposes of this Agreement OCLL, ONEM, and the ONEM Shareholders are sometimes collectively referred to as the “Parties” and individually as a “Party.”

RECITALS

 

WHEREAS, (i) the ONEM Shareholder and ONEM believe it is in their respective best interests for the ONEM Shareholders to exchange, One Thousand (1,000) shares of ONEM common stock, representing One Hundred (100%) percent of the issued and outstanding shares of ONEM (the “ONEM Shares”), an aggregate of Forty Million (40,000,000) shares of post forward split (as set forth in Section 5.5 below) common stock of OCLL and Five Million (5,000,000) shares of OCLL Series A Preferred Stock (such shares being hereinafter referred to as the “OCLL Shares”); and (ii) OCLL believes it is in its best interest and the best interest of its stockholders to acquire the ONEM Shares in exchange for the OCLL Shares, all upon the terms and subject to the conditions set forth in this Agreement (the “Share Exchange”); and,

 

WHEREAS, it is the intention of the parties that: (i) the Share Exchange shall qualify as a tax-free reorganization under Section 368(a)(1)(B) of the Internal Revenue Code of 1986, as amended (the “Code”); and (ii) the Share Exchange shall qualify as a transaction in securities exempt from registration or qualification under the Securities Act of 1933, as amended and in effect on the date of this Agreement (the “Securities Act”); and,

 

WHEREAS, it is the intention of the parties that upon the Closing (as hereinafter defined) ONEM shall become a wholly owned subsidiary of OCLL; and, 

WHEREAS, the Parities agree that the foregoing Recitals are true and correct and are hereby incorporated into this Agreement by this reference; and, 

NOW, THEREFORE, in consideration of the mutual terms, conditions and other agreements set forth herein, the parties hereto agree as follows:

ARTICLE I

 

EXCHANGE OF ONEM SHARES FOR OCLL SHARES

 

Section 1.1 

Agreements to Exchange ONEM Shares for OCLL Shares. On the Closing Date (as hereinafter defined) and upon the terms and subject to the conditions set forth in this Agreement, the ONEM Shareholders shall assign, transfer, convey and deliver the ONEM Shares to OCLL in consideration and exchange for the ONEM Shares, OCLL shall issue, transfer, convey and deliver the OCLL Shares to the ONEM Shareholders.

 

Section 1.2 

Closing and Actions at Closing. The closing of the Share Exchange (the “Closing”) shall take place remotely via the exchange of documents and signatures at such time and date as the parties hereto shall agree orally or in writing (the “Closing Date”).

Section 1.3 

Share Exchange. After Closing and contingent upon the satisfaction of the terms and conditions set forth in this Agreement, One Thousand (1,000) shares of common stock, representing One Hundred (100%) percent of the ONEM Shares shall be exchanged and delivered to OCLL and in exchange OCLL shall exchange and deliver an aggregate of Forty Million (40,000,000) shares of post forward split (as set forth in Section 5.5 below) common stock of OCLL and Five Million (5,000,000) shares of OCLL Series A Preferred Stock to the ONEM Shareholders. 

Section 1.4

Restrictions on OCLL Shares Issued Pursuant to this Agreement. The OCLL shares to be issued by OCLL pursuant to this Agreement have not been registered and are being issued pursuant to a specific exemption under the Securities Act, as well as under certain state securities laws for transactions by an issuer not involving any public offering or in reliance on limited federal preemption from such state securities registration laws, based on the suitability and investment representations made by the ONEM Shareholders to OCLL. The OCLL Shares of to be issued by OCLL pursuant to this Agreement must be held and may not be sold, transferred, or otherwise disposed of for value unless such securities are subsequently registered under the Securities Act or an exemption from such registration is available, and that the certificates representing the Shares of OCLL Common Stock issued in the Share Exchange will bear a legend in substantially the following form so restricting the sale of such securities:

1

The securities represented by this certificate have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and are “restricted securities” within the meaning of Rule 144 promulgated under the Securities Act. The securities have been acquired for investment and may not be sold or transferred without complying with Rule 144 in the absence of an effective registration or other compliance under the Securities Act.

Section 1.5

Share Exchange Procedure. The ONEM Shareholders may exchange their certificates representing the ONEM Shares by delivering such certificate(s) to OCLL duly executed and endorsed in blank (or accompanied by duly executed stock powers duly endorsed in blank), in each case in proper form for transfer, with signatures guaranteed, and, if applicable, with all stock transfer and any other required documentary stamps affixed thereto and with appropriate instructions to allow the transfer agent to issue certificates for the OCLL Shares to the holder thereof.

ARTICLE II

 

REPRESENTATIONS AND WARRANTIES OF OCLL

 

OCLL represent, warrant and agree that all of the statements in the following subsections of this Article II are true and complete as of the date hereof.

 

Section 2.1

Corporate Organization

A. 

Oculus, Inc. is a corporation duly organized, validly existing and in good standing under the laws of Nevada, and has all requisite corporate power and authority to own its properties and assets and governmental licenses, authorizations, consents and approvals to conduct its business as now conducted and is duly qualified to do business and is in good standing in each jurisdiction in which the nature of its activities makes such qualification and being in good standing necessary, except where the failure to be so qualified and in good standing will not have a Material Adverse Effect on the activities, business, operations, properties, assets, condition or results of operation of OCLL. “Material Adverse Effect” means, when used with respect to OCLL, any event, occurrence, fact, condition, change or effect, which, individually or in the aggregate, would reasonably be expected to be materially adverse to the business, operations, properties, assets, condition (financial or otherwise), or operating results of OCLL, or materially impair the ability of OCLL to perform its obligations under this Agreement, excluding any change, effect or circumstance resulting from (i) the announcement, pendency or consummation of the transactions contemplated by this Agreement; or (ii) changes in the U.S. securities markets generally.

B.

Copies of the Articles of Incorporation and Bylaws of OCLL with all amendments thereto, as of the date hereof (the “OCLL Charter Documents”), have been furnished to ONEM, if so requested, and such copies are accurate and complete as of the date hereof. The minute books of OCLL are current as required by law, contain the minutes of all meetings of the OCLL Board and its stockholders from its date of incorporation to the date of this Agreement, and adequately reflect all material actions taken by the OCLL Board and its stockholders. OCLL is not in violation of any of the provisions of the OCLL Charter Documents.

 

Section 2.2

Capitalization of OCLL. 

A.

The authorized capital stock of OCLL consists of: (i) 200,000,000 shares of common stock, par value $0.00001, of which 46,367,670 shares of common stock are issued and outstanding immediately prior to the Share Exchange; (ii) 100,000,000 shares of common stock, par value $0.00001, of which NIL shares of common stock are issued and outstanding immediately prior to the Share Exchange. 

B. 

All of the issued and outstanding shares of common stock of OCLL immediately prior to this Share Exchange are, and all shares of common stock of OCLL when issued in accordance with the terms hereof will be, duly authorized, validly issued, fully paid and non-assessable, will have been issued in compliance with all applicable U.S. federal and state securities laws and state corporate laws, and will have been issued free of preemptive rights of any security holder. The issuance of all of the shares of OCLL described in this Section 2.2 have been, or will be, as applicable, in compliance with U.S. federal and state securities laws and state corporate laws and no stockholder of OCLL has any right to rescind or bring any other claim against OCLL for failure to comply with the Securities Act, or state securities laws.

Section 2.3 

Shell Status. As of the date of this Agreement, OCLL represents that is a “shell company” as that term is defined in Rule 405 of the Securities Act and Rule 12b-2 of the Exchange Act. 

2

Section 2.4

Authorization, Validity and Enforceability of Agreements. OCLL has all corporate power and authority to execute and deliver this Agreement and all agreements, instruments and other documents to be executed and delivered in connection with the transactions contemplated by this Agreement (collectively the “Agreements”) to perform its obligations hereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery of the Agreements by OCLL and the consummation by OCLL of the transactions contemplated hereby and thereby, have been duly authorized by all necessary corporate action of OCLL, and no other corporate proceedings on the part of OCLL are necessary to authorize the Agreements or to consummate the transactions contemplated hereby and thereby. The Agreements constitute the valid and legally binding obligation of OCLL and is enforceable in accordance with its terms, except as such enforcement may be limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors rights generally. OCLL does not need to give any notice to, make any filings with, or obtain any authorization, consent or approval of any government or governmental agency or other party in order for it to consummate the transactions contemplated by any of the Agreements, resulting from the issuance of the OCLL Shares in connection with the Share Exchange.

Section 2.5 

No Conflict or Violation. Neither the execution and delivery of the Agreements by OCLL, nor the consummation by OCLL of the transactions contemplated thereby will: (i) contravene, conflict with, or violate any provision of the OCLL Charter Documents; (ii) violate any constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge or other restriction of any government, governmental agency, court, administrative panel or other tribunal to which OCLL is subject; (iii) conflict with, result in a breach of, constitute a default (or an event or condition which, with notice or lapse of time or both, would constitute a default) under, result in the acceleration of, create in any party the right to accelerate, terminate, modify or cancel, or require any notice under any agreement, contract, lease, license, instrument or other arrangement to which OCLL is a party or by which it is bound, or to which any of its assets or properties are subject; or (iv) result in or require the creation or imposition of any encumbrance of any nature upon or with respect to any of OCLL’ assets, including without limitation, the OCLL Shares.

 

Section 2.6 

Litigation. There is no action, suit, proceeding or investigation (“Action”) pending or, to the knowledge of OCLL, currently threatened against OCLL or any of its affiliates, that may affect the validity of this Agreement or the right of OCLL to enter into this Agreement or to consummate the transactions contemplated hereby or thereby. There is no Action pending or, to the knowledge of OCLL, currently threatened against OCLL or any of its affiliates, before any court or by or before any governmental body or any arbitration board or tribunal, nor is there any judgment, decree, injunction or order of any court, governmental department, commission, agency, instrumentality or arbitrator against or relating to OCLL or any of its affiliates. Neither OCLL nor any of its affiliates is a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no Action by OCLL or any of its affiliates currently pending or which OCLL or any of its affiliates intends to initiate.

Section 2.7

Compliance with Laws. OCLL has been and is in compliance with, and has not received any notice of any violation of any, applicable law, order, ordinance, regulation or rule of any kind whatsoever, including without limitation the Securities Act, the Exchange Act, the applicable rules and regulations of the SEC or the applicable securities laws and rules and regulations of any state.

 

Section 2.8 

Financial Statements. OCLL’s financial statements (the “Financial Statements”) have been prepared in accordance with generally accepted accounting principles applicable in the United States of America (“U.S. GAAP”) applied on a consistent basis, except that those Financial Statements that are not audited do not contain all footnotes required by U.S. GAAP. The Financial Statements fairly present the financial condition and operating results of OCLL as of the dates, and for the periods, indicated therein, subject to normal year-end audit adjustments. OCLL has no material liabilities (contingent or otherwise). OCLL is not a guarantor or indemnitor of any indebtedness of any other person, entity or organization. OCLL maintains a standard system of accounting established and administered in accordance with U.S. GAAP.

 

Section 2.9 

Books, Financial Records and Internal Controls. All the accounts, books, registers, ledgers, OCLL Board minutes and financial and other records of whatsoever kind of OCLL have been fully, properly and accurately kept and completed; there are no material inaccuracies or discrepancies of any kind contained or reflected therein; and they give and reflect a true and fair view of the financial, contractual and legal position of OCLL. OCLL maintains a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate actions are taken with respect to any differences.

 

Section 2.10 

No Disagreements with Accountants and Lawyers. There are no disagreements of any kind presently existing, or anticipated by OCLL to arise, between OCLL and any accountants and/or lawyers formerly or presently engaged by OCLL. OCLL is current with respect to fees owed to its accountants and lawyers.

3

 

Section 2.11 

Absence of Undisclosed Liabilities. Except as specifically disclosed herein: (A) there has been no event, occurrence or development that has resulted in or could result in a Material Adverse Effect; (B) OCLL has not incurred any liabilities, obligations, claims or losses, contingent or otherwise, including debt obligations, other than professional fees to be paid prior to Closing; (C) OCLL has not declared or made any dividend or distribution of cash or property to its shareholders, purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, or issued any equity securities other than with respect to transactions contemplated hereby; (D) OCLL has not made any loan, advance or capital contribution to or investment in any person or entity; (E) OCLL has not discharged or satisfied any lien or encumbrance or paid any obligation or liability (absolute or contingent), other than current liabilities paid in the ordinary course of business; (F) OCLL has not suffered any losses or waived any rights of material value, whether or not in the ordinary course of business, or suffered the loss of any material amount of prospective business; and (G) except for the Share Exchange, OCLL has not entered into any transaction other than in the ordinary course of business, or entered into any other material transaction, whether or not in the ordinary course of business.

 

Section 2.12 

No Undisclosed Events or Circumstances. No event or circumstance has occurred or exists with respect to OCLL or its respective businesses, properties, prospects, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by OCLL but which has not been so publicly announced or disclosed. OCLL has not provided to ONEM, or the ONEM Shareholder, any material non-public information or other information which, according to applicable law, rule or regulation, was required to have been disclosed publicly by OCLL but which has not been so disclosed, other than with respect to the transactions contemplated by this Agreement and/or the Share Exchange.

 

Section 2.13

Disclosure. This Agreement and any certificate attached hereto or delivered in accordance with the terms hereof by or on behalf of OCLL in connection with the transactions contemplated by this Agreement, when taken together, do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements contained herein and/or therein not misleading.

ARTICLE III

 

REPRESENTATIONS AND WARRANTIES OF ONEM

 

ONEM represents, warrants and agrees that all of the statements in the following subsections of this Article III, pertaining to ONEM, are true and complete as of the date hereof.

 

Section 3.1 

Corporate Organization

A. 

ONEM is a corporation duly organized, validly existing and in good standing under the laws of Delaware, and has all requisite corporate power and authority to own its properties and assets and governmental licenses, authorizations, consents and approvals to conduct its business as now conducted and is duly qualified to do business and is in good standing in each jurisdiction in which the nature of its activities makes such qualification and being in good standing necessary, except where the failure to be so qualified and in good standing will not have a Material Adverse Effect on the activities, business, operations, properties, assets, condition or results of operation of ONEM. “Material Adverse Effect” means, when used with respect to ONEM, any event, occurrence, fact, condition, change or effect, which, individually or in the aggregate, would reasonably be expected to be materially adverse to the business, operations, properties, assets, condition (financial or otherwise), or operating results of ONEM, or materially impair the ability of ONEM to perform its obligations under this Agreement, excluding any change, effect or circumstance resulting from (i) the announcement, pendency or consummation of the transactions contemplated by this Agreement; or (ii) changes in the U.S. securities markets generally.

B.

Copies of the formation documents of ONEM, or their equivalent, with all amendments thereto, as of the date hereof (the “ONEM Charter Documents”), have been furnished to OCLL, if so requested, and such copies are accurate and complete as of the date hereof. The minute books of ONEM are current as required by law, contain the minutes of all meetings of the ONEM Board and its stockholders from its date of formation to the date of this Agreement, and adequately reflect all material actions taken by the ONEM Board and its stockholders. ONEM is not in violation of any of the provisions of the ONEM Charter Documents.

 

Section 3.2 

Capitalization of ONEM. 

A.

ONEM represents and warrants that as of the Closing it shall have One Thousand (1,000) shares of common stock issued and outstanding and NIL shares of Preferred Stock issued and outstanding.

4

 

B. 

All of the issued and outstanding shares of common stock of ONEM immediately prior to this Share Exchange are, and all shares of common stock of ONEM when issued in accordance with the terms hereof will be, duly authorized, validly issued, fully paid and non-assessable, will have been issued in compliance with all applicable securities laws and corporate laws of Delaware and will have been issued free of preemptive rights of any security holder. The issuance of all of the shares of ONEM described in this Section 2.2 have been, or will be, as applicable, in compliance with U.S. federal and state securities laws and state corporate laws and no stockholder of ONEM has any right to rescind or bring any other claim against ONEM for failure to comply with the Securities Act, or state securities laws. 

Section 3.3

Shareholders of ONEM’s Common Stock. ONEM has provided OCLL a true and complete list of the holders of all issued and outstanding shares of ONEM including number of OCLL shares held as of the date of this Agreement.

Section 3.4

Directors and Officers of ONEM. The duly elected or appointed directors and the duly appointed officers of ONEM are as set out in Schedule 3.4.

Section 3.5 

Financial Statements. ONEM has kept all books and records since inception and such financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) consistently applied throughout the periods involved. The balance sheets are true and accurate and present fairly as of their respective dates the financial condition of ONEM. As of the date of such balance sheets, except as and to the extent reflected or reserved against therein, including but not limited to any previous tax liability ONEM had no liabilities or obligations (absolute or contingent) which should be reflected in the balance sheets or the notes thereto prepared in accordance with GAAP, and all assets reflected therein are properly reported and present fairly the value of the assets of ONEM, in accordance with GAAP. The statements of operations, stockholders’ equity and cash flows reflect fairly the information required to be set forth therein by GAAP.

 

The books and records, financial and otherwise, of ONEM are, in all material aspects, complete and correct and have been maintained in accordance with good business and accounting practices.

 

All of ONEM’s assets are reflected on its financial statements, and ONEM has no material liabilities, direct or indirect, matured or unmatured, contingent or otherwise which is not reflected on its financial statements.

 

Section 3.6

Information. The information concerning ONEM set forth in this Agreement is complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading.

Section 3.7 

Personal Property. ONEM possesses, and has good and marketable title of all property necessary for the continued operation of the business of ONEM as presently conducted and as represented to OCLL. All such property is used in the business of ONEM. All such property is in reasonably good operating condition (normal wear and tear excepted), and is reasonably fit for the purposes for which such property is presently used. All material equipment, furniture, fixtures and other tangible personal property and assets owned or leased by ONEM and its subsidiaries is owned by ONEM or its subsidiaries free and clear of all liens, security interests, charges, encumbrances, and other adverse claims.

Section 3.8

Intellectual Property. ONEM represents and warrants that all trademarks and trademark applications, and all patents and patent applications, as set forth in Schedule 3.8, and any trade secrets, and “know-how” held relating to business of ONEM, and all other intangible assets, in ONEM’s possession or that may be reasonably acquired by ONEM any other proprietary information and trade secrets relating to the business of ONEM (collectively the “Intellectual Property”) shall remain the intellectual property of ONEM as of the date of Closing of this Agreement and that ONEM shall take any steps reasonable to assign or otherwise transfer any Intellectual Property right to OCLL, as necessary to protect OCLL’s rights to the same. Further, ONEM owns, free and clear of any encumbrance, or has the valid right to sell all Intellectual Property used by in its business, as currently conducted. ONEM represents that it has not received any written complaint, claim or notice alleging any such infringement, violation or misappropriation. Additionally, ONEM has taken reasonable precautions (i) to protect its rights in its Intellectual Property and (ii) to maintain the confidentiality of its trade secrets, know-how and other confidential Intellectual Property, related to the business and to ONEM’s knowledge, there have been no acts or omissions by the managers, members, employees and agents of ONEM, the result of which would be to materially compromise the rights of ONEM to apply for or enforce appropriate legal protection of ONEM’s Intellectual Property. 

5

Section 3.9

Material Contracts and Transactions. Schedule 3.9 attached hereto lists each material contract, agreement, license, permit, arrangement, commitment, instrument or contract to which ONEM or any of its subsidiaries is a party (each, a “Contract”). Each Contract is in full force and effect, and there exists no material breach or violation of or default by ONEM or any of its subsidiaries under any Contract, or any event that with notice or the lapse of time, or both, will create a material breach or violation thereof or default under any Contract by ONEM or any of its subsidiaries. The continuation, validity, and effectiveness of each Contract will in no way be affected by the consummation of the Transaction or any of the transactions contemplated in this Agreement. There exists no actual or threatened termination, cancellation, or limitation of, or any amendment, modification, or change to any Contract.

Section 3.10

Subsidiaries. Except as set forth on Schedule 3.10, ONEM does not have any subsidiaries or agreements of any nature to acquire any subsidiary or to acquire or lease any other business operations. Each subsidiary of ONEM is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation and has the requisite corporate power and authority to own, lease and to carry on its business as now being conducted. Each subsidiary of ONEM is duly qualified to do business and is in good standing as a corporation in each of the jurisdictions in which ONEM owns property, leases property, does business, or is otherwise required to do so, where the failure to be so qualified would have a material adverse effect on the business of ONEM and its subsidiaries taken as a whole. ONEM owns all of the shares of each subsidiary of ONEM and there are no outstanding options, warrants, subscriptions, conversion rights, or other rights, agreements, or commitments obligating any subsidiary of ONEM to issue any additional common shares of such subsidiary, or any other securities convertible into, exchangeable for, or evidencing the right to subscribe for or acquire from any subsidiary of ONEM any shares of such subsidiary.

Section 3.11

Absence of Certain Changes or Events. As of the date of this Agreement, (a) there has not been any material adverse change in the business, operations, properties, assets, or condition (financial or otherwise) of ONEM; and (b) ONEM has not: (i) declared or made, or agreed to declare or make, any payment of dividends or distributions of any assets of any kind whatsoever to stockholders or purchased or redeemed, or agreed to purchase or redeem, any of its shares; (ii) made any material change in its method of management, operation or accounting; (iii) entered into any other material transaction other than in the ordinary course of its business; or (iv) made any increase in or adoption of any profit sharing, bonus, deferred compensation, insurance, pension, retirement, or other employee benefit plan, payment, or arrangement made to, for, or with its officers, directors, or employees.

 

Section 3.12

Litigation and Proceedings. There are no actions, suits, proceedings, or investigations pending or, to the knowledge of ONEM after reasonable investigation, threatened by or against ONEM or affecting ONEM or its properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind. ONEM does not have any knowledge of any material default on its part with respect to any judgment, order, injunction, decree, award, rule, or regulation of any court, arbitrator, or governmental agency or instrumentality.

 

Section 3.13

Compliance With Laws and Regulations. To the best of its knowledge, ONEM has complied with all applicable statutes and regulations, except to the extent that noncompliance would not materially and adversely affect the business, operations, properties, assets, or condition of ONEM or except to the extent that noncompliance would not result in the occurrence of any material liability for ONEM. This compliance includes, but is not limited to, the filing of all reports to date with relevant authorities.

 

Section 3.14

Approval of Agreement. The Board of Directors of ONEM has authorized the execution and delivery of this Agreement by ONEM and has approved this Agreement and the transactions contemplated hereby.

 

Section 3.15

Valid Obligation. This Agreement and all agreements and other documents executed by ONEM in connection herewith constitute the valid and binding obligation of ONEM, enforceable in accordance with its or their terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and subject to the qualification that the availability of equitable remedies is subject to the discretion of the court before which any proceeding therefore may be brought.

6

ARTICLE IV

 

REPRESENTATIONS AND WARRANTIES OF ONEM SHAREHOLDERS

 

The ONEM Shareholder hereby severally and not jointly represents and warrants to OCLL:

 

Section 4.1 

Authority. The ONEM Shareholders has the right, power, authority and capacity to execute and deliver this Agreement to which such ONEM Shareholders is a party, to consummate the transactions contemplated by this Agreement, and to perform such ONEM Shareholder’s obligations under this Agreement. This Agreement has been duly and validly authorized and approved, executed and delivered by the ONEM Shareholders. Assuming this Agreement has been duly and validly authorized, executed and delivered by the parties thereto other than such ONEM Shareholders, this Agreement is duly authorized, executed and delivered by the ONEM Shareholders and constitutes the legal, valid and binding obligations of the ONEM Shareholders, enforceable against the ONEM Shareholders in accordance with their respective terms, except as such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors rights generally.

 

Section 4.2 

No Conflict. Neither the execution or delivery by the ONEM Shareholders of this Agreement to which the ONEM Shareholders are a party nor the consummation or performance by the ONEM Shareholders of the transactions contemplated hereby or thereby will, directly or indirectly, (a) contravene, conflict with, or result in a violation of any provision of the organizational documents of the ONEM Shareholders; (b) contravene, conflict with, constitute a default (or an event or condition which, with notice or lapse of time or both, would constitute a default) under, or result in the termination or acceleration of, any agreement or instrument to which any of the ONEM Shareholders are a party or by which the properties or assets of the ONEM Shareholders is bound; or (c) contravene, conflict with, or result in a violation of, any law or order to which any of the ONEM Shareholders, or any of the properties or assets of the ONEM Shareholders, may be subject.

 

Section 4.3 

 Litigation. There is no pending Action against the ONEM Shareholders that involves the ONEM Shares or that challenges, or may have the effect of preventing, delaying or making illegal, or otherwise interfering with, any of the transactions contemplated by this Agreement or the business of ONEM and, to the knowledge of the ONEM Shareholders, no such Action has been threatened, and no event or circumstance exists that is reasonably likely to give rise to or serve as a basis for the commencement of any such Action.

 

Section 4.4 

Ownership of Shares. The ONEM Shareholders are the record and beneficial owners of the ONEM Shares. The ONEM Shareholder are not the record or beneficial owners of any other shares of ONEM. The ONEM Shareholders have and shall transfer at the Closing, good and marketable title to the ONEM Shares, free and clear of all liens, claims, charges, encumbrances, pledges, mortgages, security interests, options, rights to acquire, proxies, voting trusts or similar agreements, restrictions on transfer or adverse claims of any nature whatsoever, excepting only restrictions on future transfers imposed by applicable law.

 

Section 4.5 

Pre-emptive Rights. The ONEM Shareholders have no pre-emptive rights or any other rights to acquire any shares of ONEM that have not been waived or exercised.

ARTICLE V

 

CONDITIONS TO THE OBLIGATIONS OF ONEM AND THE ONEM SHAREHOLDERS

 

The obligations of ONEM to consummate the transactions contemplated by this Agreement are subject to the fulfillment, at or before the Closing Date, of the following conditions, any one or more of which may be waived by ONEM or the ONEM Shareholders, as the case may be, in their sole discretion:

 

Section 5.1 

Representations and Warranties of OCLL. All representations and warranties made by OCLL in this Agreement shall be true and correct in all material respects on and as of the Closing Date.

 

Section 5.2 

Agreements and Covenants. OCLL shall have performed and complied in all material respects with all agreements and covenants required by this Agreement to be performed or complied with on or prior to the Closing Date.

 

Section 5.3 

Consents and Approvals. All consents, waivers, authorizations and approvals of any governmental or regulatory authority, domestic or foreign, and of any other person, firm or corporation, required in connection with the execution, delivery and performance of this Agreement shall be in full force and effect on the Closing Date.

7

 

Section 5.4 

No Violation of Orders. No preliminary or permanent injunction or other order issued by any court or governmental or regulatory authority, domestic or foreign, nor any statute, rule, regulation, decree or executive order promulgated or enacted by any government or governmental or regulatory authority, which declares this Agreement invalid in any respect or prevents the consummation of the transactions contemplated hereby, or which materially and adversely affects the assets, properties, operations, prospects, net income or financial condition of OCLL shall be in effect; and no action or proceeding before any court or governmental or regulatory authority, domestic or foreign, shall have been instituted or threatened by any government or governmental or regulatory authority, domestic or foreign, or by any other person or entity, which seeks to prevent or delay the consummation of the transactions contemplated by this Agreement or which challenges the validity or enforceability of this Agreement.

 

Section 5.5 

Obligations Prior to Closing. OCLL must have caused the following to occur prior to Closing: 

A. 

OCLL shall have filed with the Financial Industry Regulatory Authority (“FINRA”) such paperwork as necessary to complete a Two-for-One (2:1) forward split (the “Forward Split”) of the OCLL common stock; 

B. 

OCLL shall increase its authorized shares from the present amount of 200,000,000 to 500,000,000, OCLL shall effectuate this by filing Amended Articles of Incorporation with the Secretary of State of Nevada; 

C. 

OCLL shall have effectuated a name change to better reflect the post-transaction business of the Company, OCLL shall effectuate this by filing Amended Articles of Incorporation with the Secretary of State of Nevada; 

D. 

OCLL shall have caused the cancellation of 35,000,000 pre-Forward Split shares of common stock, which shall be canceled and return to the Company’s in exchange for the OCLL Shares; and, 

E. 

OCLL shall deliver the following documents to ONEM: (i) share certificates evidencing the OCLL Shares registered in the name of the ONEM Shareholder; (ii) this Agreement duly executed; (iii) such other documents as ONEM or the ONEM Shareholder may reasonably request for the purpose of evidencing the accuracy of any of the representations and warranties of OCLL, evidencing the performance of, or compliance by OCLL with any covenant or obligation required to be performed or complied with by OCLL, evidencing the satisfaction of any condition referred to in this Article V, or otherwise facilitating the consummation or performance of any of the transactions contemplated by this Agreement. 

Section 5.6 

Financing. OCLL shall have the right, but not the obligation to raise capital of up to Three Million dollars ($3,000,000) prior to the Closing of this Agreement (the “Financing”). The Financing may be accomplished through the sale or placement of shares of the Company’s restricted common stock. 

Section 5.7 

No Material Adverse Effect. There shall not have been any event, occurrence or development that has resulted in or could result in a Material Adverse Effect on or with respect to OCLL.

Section 5.8 

Employment Agreements. OCLL will have received from ONEM copies of all agreements or arrangements that evidence the employment of all of the hourly and salaried employees of ONEM as set forth on Schedule 5.8 attached hereto, which constitute all of the employees reasonably necessary to operate the business of ONEM substantially as presently operated.

ARTICLE VI

 

CONDITIONS TO THE OBLIGATIONS OF OCLL

 

The obligations of OCLL to consummate the transactions contemplated by this Agreement are subject to the fulfillment, at or before the Closing Date, of the following conditions, any one or more of which may be waived by OCLL in its sole discretion:

 

Section 6.1 

Representations and Warranties of ONEM and the ONEM Shareholder. All representations and warranties made by ONEM and the ONEM Shareholder on behalf of themselves individually in this Agreement shall be true and correct on and as of the Closing Date.

Section 6.2 

Approval by Majority Consent. The holders of at least a majority (51%) of the outstanding shares of common stock of ONEM must approve this Agreement by written consent prior to the Closing Date. 

 

Section 6.3 

Agreements and Covenants. ONEM and the ONEM Shareholder shall have performed and complied in all material respects with all agreements and covenants required by this Agreement to be performed or complied with by each of them on or prior to the Closing Date.

8

 

Section 6.4 

Consents and Approvals. All consents, waivers, authorizations and approvals of any governmental or regulatory authority, domestic or foreign, and of any other person, firm or corporation, required in connection with the execution, delivery and performance of this Agreement, shall have been duly obtained and shall be in full force and effect on the Closing Date.

 

Section 6.5 

No Violation of Orders. No preliminary or permanent injunction or other order issued by any court or other governmental or regulatory authority, domestic or foreign, nor any statute, rule, regulation, decree or executive order promulgated or enacted by any government or governmental or regulatory authority, domestic or foreign, that declares this Agreement invalid or unenforceable in any respect or which prevents the consummation of the transactions contemplated hereby, or which materially and adversely affects the assets, properties, operations, prospects, net income or financial condition of ONEM shall be in effect; and no action or proceeding before any court or government or regulatory authority, domestic or foreign, shall have been instituted or threatened by any government or governmental or regulatory authority, domestic or foreign, or by any other person or entity, which seeks to prevent or delay the consummation of the transactions contemplated by this Agreement or which challenges the validity or enforceability of this Agreement.

Section 6.6 

Documents. ONEM and the ONEM Shareholder must deliver to OCLL at the Closing:

A. 

ONEM shall have prepared and presented to OCLL two years of audited financial statements, such statements shall have been audited by a Public Company Accounting Oversight Board registered and approved audit firm; 

B. 

share certificates evidencing the number of ONEM Shares, along with executed share transfer forms transferring such ONEM Shares to OCLL;

C.

this Agreement to which the ONEM and the ONEM Shareholder are each a party, duly executed; and

D. 

such other documents as OCLL may reasonably request for the purpose of (i) evidencing the accuracy of any of the representations and warranties of ONEM and the ONEM Shareholder, (ii) evidencing the performance of, or compliance by ONEM and the ONEM Shareholder with, any covenant or obligation required to be performed or complied with by ONEM and the ONEM Shareholder, as the case may be, (iii) evidencing the satisfaction of any condition referred to in this Article VI, or (iv) otherwise facilitating the consummation or performance of any of the transactions contemplated by this Agreement.

Section 6.7

No Claim Regarding Stock Ownership or Consideration. There must not have been made or threatened by any person, any claim asserting that such person (a) is the holder of, or has the right to acquire or to obtain beneficial ownership of the ONEM Shares, or any other stock, voting, equity, or ownership interest in, ONEM, or (b) is entitled to all or any portion of the OCLL Shares.

 

ARTICLE VII

 

SURVIVAL AND INDEMNIFICATION

 

Section 7.1 

Survival of Provisions. The respective representations, warranties, covenants and agreements of each of the parties to this Agreement (except covenants and agreements which are expressly required to be performed and are performed in full on or before the Closing Date) shall expire on the first day of the three-year anniversary of the Closing Date (the “Survival Period”). The right to indemnification, payment of damages or other remedy based on such representations, warranties, covenants, and obligations will not be affected by any investigation conducted with respect to, or any knowledge acquired (or capable of being acquired) at any time, whether before or after the execution and delivery of this Agreement, with respect to the accuracy or inaccuracy of or compliance with, any such representation, warranty, covenant, or obligation. The waiver of any condition based on the accuracy of any representation or warranty, or on the performance of or compliance with any covenant or obligation, will not affect the right to indemnification, payment of damages, or other remedy based on such representations, warranties, covenants, and obligations.

9

 

Section 7.2 

Indemnification.

 

A.

Indemnification Obligations in favor of OCLL. From and after the Closing Date until the expiration of the Survival Period, ONEM shall reimburse and hold harmless OCLL and its shareholders (such person and their heirs, executors, administrators, agents, successors and assigns is referred to herein as a “OCLL Indemnified Party”) against and in respect of any and all damages, losses, settlement payments, in respect of deficiencies, liabilities, costs, expenses and claims suffered, sustained, incurred or required to be paid by such OCLL Indemnified Party, and any and all actions, suits, claims, or legal, administrative, arbitration, governmental or other procedures or investigation against any OCLL Indemnified Party, which arises or results from a third-party claim brought against a OCLL Indemnified Party to the extent based on a breach of the representations and warranties with respect to the business, operations or assets of ONEM. All claims of OCLL pursuant to this Section 7.2 shall be brought by OCLL on behalf of OCLL and those Persons who were stockholders of OCLL immediately prior to the Closing Date. In no event shall any such indemnification payments exceed $50,000 in the aggregate from ONEM. No claim for indemnification may be brought under this Section 7.2(A) unless all claims for indemnification, in the aggregate, total more than $10,000.

B.

Indemnification Obligations in favor of ONEM and the ONEM Shareholder. From and after the Closing Date until the expiration of the Survival Period, OCLL and the OCLL shareholders shall indemnify and hold harmless ONEM, the ONEM Shareholder, and his respective officers, directors, agents, attorneys and employees, and each person, if any, who controls or may “control” (within the meaning of the Securities Act) any of the forgoing persons or entities (each a “ONEM Indemnified Person”) from and against any and all losses, costs, damages, liabilities and expenses arising from claims, demands, actions, causes of action, including, without limitation, legal fees (collectively, “Damages”) arising out of: (i) any breach of representation or warranty made by OCLL in this Agreement and in any certificate delivered by OCLL pursuant to this Agreement; (ii) any breach by OCLL of any covenant, obligation or other agreement made by OCLL in this Agreement; and (iii) a third-party claim based on any acts or omissions by OCLL. In no event shall any such indemnification payments exceed $50,000 in the aggregate from OCLL. No claim for indemnification may be brought under this Section 7.2(B) unless all claims for indemnification, in the aggregate, total more than $10,000.

ARTICLE VIII

 

MISCELLANEOUS PROVISIONS

 

Section 8.1 

Successors and Assigns. This Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors and assigns; provided that no party shall assign or delegate any of the obligations created under this Agreement without the prior written consent of the other parties.

 

Section 8.2 

Fees and Expenses. Except as otherwise expressly provided in this Agreement, all legal and other fees, costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by each Party, as incurred respectively.

 

Section 8.3 

Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been given or made if in writing and delivered personally or 7 days after being sent by registered or certified mail (postage prepaid, return receipt requested) to the parties at the addresses set forth in the Preamble of this Agreement, or to such other persons or at such other addresses as shall be furnished by any party by like notice to the others, and such notice or communication shall be deemed to have been given or made as of the date so delivered or mailed. No change in any of such addresses shall be effective insofar as notices under this Section 8.3 are concerned unless notice of such change shall have been given to such other party hereto as provided in this Section 8.3.

 

Section 8.4 

Entire Agreement. This Agreement, together with the exhibits hereto, represents the entire agreement and understanding of the parties with reference to the transactions set forth herein and no representations or warranties have been made in connection with this Agreement other than those expressly set forth herein or in the exhibits, certificates and other documents delivered in accordance herewith. This Agreement supersedes all prior negotiations, discussions, correspondence, communications, understandings and agreements between the parties relating to the subject matter of this Agreement and all prior drafts of this Agreement, all of which are merged into this Agreement. No prior drafts of this Agreement and no words or phrases from any such prior drafts shall be admissible into evidence in any action or suit involving this Agreement.

 

Section 8.5 

Severability. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible so as to be valid and enforceable.

10

 

Section 8.6 

Titles and Headings. The Article and Section headings contained in this Agreement are solely for convenience of reference and shall not affect the meaning or interpretation of this Agreement or of any term or provision hereof.

 

Section 8.7 

Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall be considered one and the same agreement. Fax and PDF copies shall be considered originals for all purposes.

 

Section 8.8 

Convenience of Forum; Consent to Jurisdiction. The parties to this Agreement, acting for themselves and for their respective successors and assigns, without regard to domicile, citizenship or residence, hereby expressly and irrevocably elect as the sole judicial forum for the adjudication of any matters arising under or in connection with this Agreement, and consent and subject themselves to the jurisdiction of, the courts of the State of Nevada, and/or the U.S. District Court for Nevada, in respect of any matter arising under this Agreement. Service of process, notices and demands of such courts may be made upon any party to this Agreement by personal service at any place where it may be found or giving notice to such party as provided in Section 8.3.

 

Section 8.9 

Enforcement of the Agreement. The parties hereto agree that irreparable damage would occur if any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereto, this being in addition to any other remedy to which they are entitled at law or in equity.

 

Section 8.10 

Governing Law. This Agreement shall be governed by and interpreted and enforced in accordance with the laws of the State of Nevada without giving effect to the choice of law provisions thereof.

 

Section 8.11 

Amendments and Waivers. Except as otherwise provided herein, no amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by all of the parties hereto. No waiver by any party of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any such prior or subsequent occurrence.

[SIGNATURE PAGE FOLLOWS]

11

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

 

OCULUS, INC.

Per: 

/s/ Robert J Wagner                                       

 

Name: Robert J. Wagner

Title: President and Chief Executive Officer

 

ONE MEDIA ENTERPRISES LIMITED 

Per: 

/s/ Robert J Wagner                                       

 

Name: Robert J. Wagner

Title: President and Chief Executive Officer

 

ONE MEDIA ENTERPRISES LIMITED 

SHAREHOLDERS

 

Per: 

/s/ Robert J Wagner                                       

 

Name: Robert J. Wagner, on behalf of the 

Shareholders representing 

100% of the issued and outstanding shares of 

One Media Enterprises Limited 

12

DISCLOSURE SCHEDULE

to the

SHARE EXCHANGE AGREEMENT 

By and Among

OCULUS, INC., 

ONE MEDIA ENTERPRISES LIMITED, 

AND 

THE SHAREHOLDERS OF ONE MEDIA ENTERPRISES LIMITED

These Disclosure Schedules have been prepared pursuant to the Share Exchange Agreement (the “Agreement”) by and among OCULUS INC., a Nevada corporation (“OCLL”), ONE MEDIA ENTERPRISES LIMITED (“ONEM”), and the individual shareholders of ONEM. Except as otherwise defined herein, capitalized terms used herein will have the same meaning given to them in the Share Exchange Agreement. Schedule and paragraph numbers herein correspond to the Section and Subsection numbering in applicable Article of the Share Exchange Agreement. Section and Subsection headings contained herein are included for purposes of identifying the relevant disclosures and for the convenience of the reader and are not intended to supplement or modify the meaning of the disclosures in any way.

13

SCHEDULE 3.4

DIRECTORS AND OFFICERS OF ONEM

Robert J. Wagner - CEO, President, Director

Irving Aronson - Director

14

SCHEDULE 3.8

INTELLECTUAL PROPERTY

						
	 
	Country:

	Title of Property:

	Reference Number:

	Description:

	Filing Date:

	1.

	 
	 
	 
	Intentionally Omitted

	 

	2.

	 
	 
	 
	Intentionally Omitted

	 

15

SCHEDULE 3.9

MATERIAL CONTRACTS

				
	 
	With:

	Dated:

	Material Terms/Description:

	1.

	Intentionally Omitted

	 
	 

	2.

	Intentionally Omitted

	 
	 

16

SCHEDULE 3.10

SUBSIDIARIES OF ONEM

One Media Partners Inc.

17

SCHEDULE 5.8 

ONEM EMPLOYMENT AGREEMENTS AND ARRANGEMENTS

As of the date of this Agreement, the following hourly and salaried employees of ONEM are reasonably necessary to operate the business of ONEM as substantially presently operated:

			
	 
	Name of Party

	Date of Agreement 

	1.

	 Intentionally Omitted

	 

	2.

	Intentionally Omitted

	 

18Exhibit
10.1

 

AMENDED
AND RESTATED EARLY ACCESS AGREEMENT

 

This
exclusive Early Access Agreement (“Agreement”) is made and entered into the 20th day of May, 2016, (“Effective
Date”) by and between

 

Hemispherx
Biopharma, Inc, a company formed and registered under the laws of Delaware and located at One Penn Center, 1617 JFK Boulevard,
Suite 500, Philadelphia, PA 19103, U.S.A. (hereinafter referred to as “HEMISPHERX”),

 

and

 

Impatients
N.V., a company formed and registered under the laws of the Netherlands, and located at Pilotenstraat 45, 1059 CH, Amsterdam,
The Netherlands (hereinafter referred to as “IMPATIENTS”),

 

hereinafter
each of HEMISPHERX and IMPATIENTS, referred individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

WHEREAS,
HEMISPHERX has developed, and is developing the Product (as defined below), and owns or controls certain patent rights, and technical
and scientific information relating to, and the global exclusive rights to distribute, market and sell Product,

 

WHEREAS,
IMPATIENTS specialises under the brand myTomorrows in services related to the supply and distribution of products to patients
in Early Access Programs (also referred to as EAP and as defined below) through a patient and physician platform (hereinafter
referred to as the “myTomorrows platform”),

 

WHEREAS,
HEMISPHERX is willing to grant IMPATIENTS the exclusive right to develop and execute Early Access Programs in the Territory (as
defined below) and to supply quantities of Product to IMPATIENTS for these Early Access Programs in the Territory,

 

WHEREAS,
IMPATIENTS agrees to accept such right and to use the Product for Early Access Programs from HEMISPHERX pursuant to the terms
of this Agreement, and

 

WHEREAS,
the Parties wish to set forth the terms and conditions under which HEMISPHERX grants the exclusive right and supplies the Product
and IMPATIENTS implements the Early Access Program.

 

NOW
THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties hereto, intending
to be legally bound, agree as follows:

 

    	 1
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

1.
Definitions

 

The
following terms when used in this Agreement, shall have the meanings set forth in this clause:

 

	1.1	“Accounting
    Standards” with respect to a Party means that such Party shall maintain records and books of accounts in accordance
    with International Financial Reporting Standards as issued by the International Accounting Standards Board.
	 	 
	1.2	“Affiliate”
    means, as to any person or entity, any other person or entity, which controls, is controlled by, or is under common control
    with such person or entity. A person or entity shall be regarded as in control of another entity only if it owns or controls,
    directly or indirectly, at least fifty percent (50%) of the equity securities or other ownership interests in the subject
    entity entitled to vote in the election of directors or with the power to direct or elect management of such subject entity.
	 	 
	1.3	“HEMISPHERX
    Patents” means all of the Patents that are (a) under Control by HEMISPHERX or any of its Affiliates as of the Effective
    Date or at any time during the Term, and (b) reasonably necessary or useful (or, with respect to Patent applications, would
    be reasonably necessary or useful if such Patent applications were to issue as Patents) for the development, manufacture,
    or use or sale of the Product.
	 	 
	1.4	“Applicable
    Law” means federal, state, local, national and supra-national laws, statutes, rules, and regulations, including
    any rules, regulations, guidelines, or other requirements of the Regulatory Authorities, major national securities exchanges
    or major securities listing organizations, that may be in effect from time to time during the Term and applicable to a particular
    activity and/or country or other jurisdiction hereunder.
	 	 
	1.5	“Confidential
    Information” means any Information provided orally, visually, in writing or other form by or on behalf of one Party
    to the other Party in connection with this Agreement, whether prior to, on, or after the Effective Date, including information
    relating to the terms of this Agreement, the Product (including the Regulatory Documentation and Regulatory Data), any use
    of the Product, any know-how with respect thereto developed by or on behalf of the disclosing Party or its Affiliates, or
    the scientific, regulatory or business affairs or other activities of either Party. Notwithstanding the foregoing, (a) jointly
    owned Know-How shall be deemed to be the Confidential Information of both Parties, and both Parties shall be deemed to be
    the receiving Party and the disclosing Party with respect thereto; and (b) after IMPATIENTS proceeds with the EAP, all Regulatory
    Documentation developed by IMPATIENTS shall be deemed to be the Confidential Information of HEMISPHERX, and HEMISPHERX shall
    be deemed to be the disclosing Party and IMPATIENTS shall be deemed to be the receiving Party with respect thereto.
	 	 
	1.6	“Control”
    means, with respect to any item of Information, Regulatory Documentation, material, Patent, or other property right existing
    on or after the Effective Date and during the Term, the possession of the right, whether directly or indirectly, and whether
    by ownership, license, covenant not to sue, or otherwise (other than by operation of the license and other grants herein),
    to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such
    Information, Regulatory Documentation, material, Patent, or other property right as provided for herein without violating
    the terms of any agreement or other arrangement with any third party; provided, however, neither Party shall be deemed to
    Control any item of Information, Regulatory Documentation, material, Patent, or other property right of a third party if access
    requires or triggers a payment obligation.

 

    	 2
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

	1.7	“Early
    Access Program” or “EAP” means the activities directed to (a) the education of physicians and
    patients regarding the possibility of early access to innovative medical treatments not yet the subject of a Marketing Authorization
    through named-patient use, compassionate use, expanded access and hospital exemption (b) patient and physician outreach related
    to the platform, (c) the securing of Early Access Approvals, for the use of such treatments, (d) the distribution and sale
    of such treatments pursuant to such Early Access Approvals, (e) pharmacovigilance activities in accordance with the Pharmacovigilance
    agreement, attached as Exhibit 6 and/or (f) to the extent permitted by Applicable Law, the collection of data, including but
    not limited to patient-reported outcomes, doctor-reported experiences and registry data as set out in more detail in Exhibit
    9.
	 	 
	1.8	“EAP
    Plan” means the plan to be agreed by the JSC for the initiation and performance of an Early Access Program for Product
    in the Field. The EAP Plan will be attached hereto as Exhibit 1.
	 	 
	1.9	“Early
    Access Approvals” means the permissions, exemptions, approvals, authorizations and/or waivers required by Regulatory
    Authorities for medical treatments, not subject of a Marketing Authorization in the relevant country, to be sold to a pharmacy
    or wholesaler, to be dispensed to a physician, to be administered to and/or used by a patient.
	 	 
	1.10	“Field”
    means treatment of chronic fatigue syndrome.
	 	 
	1.11	“First
    Commercial Sale” means, with respect to a Product and a country, the first sale for monetary value for ultimate
    use by the patient of such Product in such country after Marketing Authorization for such Product has been obtained in such
    country. Sales prior to receipt of Marketing Authorization for such Product, such as so-called “treatment IND sales,”
    “named patient sales,” or other “compassionate use sales,” shall not be construed as a First Commercial
    Sale.
	 	 
	1.12	“Good
    Manufacturing Practice” or “GMP” means the current good manufacturing practices applicable from
    time to time to the manufacturing of a Product or any intermediate thereof pursuant to Applicable Law.
	 	 
	1.13	“Information”
    means knowledge of a technical, scientific, business, and other nature, including know-how, technology, means, methods, processes,
    practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings,
    assembly procedures, computer programs, apparatuses, specifications, data, results and other material, Regulatory Data, and
    other biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical,
    safety, manufacturing and quality control data and information, including study designs and protocols; assays, and biological
    methodology; in each case (whether or not confidential, proprietary, patented or patentable, of commercial advantage or not)
    in written, electronic or any other form now known or hereafter developed.

 

    	 3
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

	1.14	“Joint
    Steering Committee or JSC” means the joint steering committee to be established by the Parties as referred to in
    Clause 2.
	 	 
	1.15	“Know
    How” means information and materials, whether or not confidential, including, but not limited to, pharmaceutical,
    chemical, products, economic and commercial information, including and not limited to all market information, strategies and
    tactics relevant to the Product in the Territory and any lists of physicians and/or clinicians active in the Field in the
    Territory, technical and non-technical manufacturing process and equipment data and information, product and process validation
    data, the results of tests on products, reports and results of product assays, pre-clinical and clinical studies, and drawings,
    plans, diagrams, specifications and/or other documents containing said information relating to the Product.
	 	 
	1.16	“Manufacturer”
    means the legal entity that physically manufactures and/or fills and/or finishes and/or labels and/or stockpiles cGMP grade
    Product.
	 	 
	1.17	“Marketing
    Authorization” means, with respect to a country, region or other jurisdiction in the Territory and in the Field,
    any and all approvals (including Drug Approval Applications), licenses, registrations, or authorizations of any Regulatory
    Authority necessary to commercially distribute, sell, or market Product in the Field in such country or other jurisdiction,
    including, where applicable, (a) pre- and post-approval regulatory approvals (including any prerequisite manufacturing approval
    or authorization related thereto), and (b) approval of Product labeling in the Field.
	 	 
	1.18	“Material
    Event” means, in the context of the EAP, any event which would, in HEMISPHERX’s reasonable opinion, (a) adversely
    affect HEMISPHERX’s ability to market and distribute the Product outside of the EAP, including but not limited to its
    ability to obtain Marketing Authorisation in any country or region, (b) adversely effect HEMISPHERX’s ability to use
    its intellectual property relating to its brand or the Product, or (c) bring HEMISPHERX’s business into disrepute. For
    the avoidance of doubt, a Material Event shall not include any event relating to the performance of pharmacovigilance activities
    in relation to which the Parties have entered into the Pharmacovigilance Agreement.
	 	 
	1.19	“Net
    EAP Sales” means the gross amount invoiced by IMPATIENTS or its affiliates to non-affiliated third parties for the
    sale of Product, less the following reasonable and customary deductions consistent with IMPATIENTS’ cash or accrual
    accounting method to the extent applicable to such invoiced amounts (to the extent each is actually incurred and included
    in the invoiced gross sales price) in accordance with Accounting Standards:

 

	 	(a)	all
    mutually agreed trade discounts or rebates;
	 	 	 
	 	(b)	amounts
    for claims, allowances or credits for rejections or returns;
	 	 	 
	 	(c)	packaging,
    handling fees and costs of freight, insurance, sales taxes, duties and other governmental charges (including value added tax),
    but excluding what is commonly known as income taxes.

 

    	 4
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

The
specific deductions, as set out in Exhibit 8, taken under, and the general provision of, (a) through (c) above may be adjusted
periodically after agreement between both Parties as necessary to reflect amounts actually incurred.

 

	1.20	“Net
    Sales” means the gross amount invoiced by HEMISPHERX or its affiliates to non-affiliated third parties for the sale
    of Product, less the following reasonable and customary deductions consistent with HEMISPHERX’s cash or accrual accounting
    method to the extent applicable to such invoiced amounts (to the extent each is actually incurred and included in the invoiced
    gross sales price) in accordance with Accounting Standards:

 

	 	(a)	all
    mutually agreed trade discounts, or rebates;
	 	 	 
	 	(b)	amounts
    for claims, allowances or credits for rejections or returns;;
	 	 	 
	 	(c)	packaging,
    handling fees and costs of freight, insurance, sales taxes, duties and other governmental charges (including value added tax),
    but excluding what is commonly known as income taxes.

 

The
specific deductions taken under, and the general provision of, (a) through (c) above may be adjusted periodically after agreement
between both Parties as necessary to reflect amounts actually incurred.

 

For
the avoidance of doubt, Net Sales shall not include sales for resale to Affiliates of HEMISPHERX.

 

For
purpose of this definition 1.20, a sale shall also include a transfer or other disposition for consideration other than cash,
in which case such consideration shall be valued at the fair market value thereof. Transfers or dispositions for charitable purposes
or for pre-clinical, clinical, regulatory or governmental purposes prior to receiving Marketing Authorization are not considered
a “sale”.

 

	1.21	“Patents”
    means (a) all national, regional and international patent applications, including provisional patent applications, and all
    applications claiming priority therefrom, including divisionals, continuations, continuations-in-part, provisionals, converted
    provisionals and continued prosecution applications; (b) any and all national patents issued or granted from the foregoing
    patent applications, including utility patents, utility models, petty patents and design patents and certificates of invention;
    (c) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations,
    reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing
    patents or patent applications ((a) and (b)); and (d) any similar rights, including so-called pipeline protection or any importation,
    revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing patent
    applications and patents.
	 	 
	1.22	“Patient
    on Treatment” means patients that have met all the criteria to receive the Product under an EAP as set out in the
    EAP Plan and who have had the Product prescribed for them.

 

    	 5
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

	1.23	Pharmacovigilance
    Agreement” or “PhVA” means the pharmacovigilance agreement attached as Exhibit 6.
	 	 
	1.24	“Price”
    means the price of Product invoiced by IMPATIENTS to third parties other than Affiliates of IMPATIENTS in accordance with
    Exhibit 4 excluding any VAT or other taxes or levies that are applicable.
	 	 
	1.25	“Product”
    means all available stock-keeping units (SKU)’s of the product referred to as of the Effective Date, as Ampligen®,
    a double-stranded RNA product, supplied ready packed and labeled, such labeling to include the Ampligen Trademark
    and the fact that the Product is manufactured and supplied by HEMISPHERX on both primary and secondary containers, quality
    tested and QP released in accordance with applicable pharmaceutical law and regulations.
	 	 
	1.26	“Quality
    Agreement or QA “ means the quality agreement attached as Exhibit 5 to this Agreement.
	 	 
	1.27	“Regulatory
    Authority” means any applicable supra-national, federal, national, regional, state, provincial, or local governmental
    or regulatory authority, agency, department, bureau, commission, council, or other entities (e.g., the FDA, EMA and PMDA)
    regulating or otherwise exercising authority with respect to activities contemplated in this Agreement.
	 	 
	1.28	“Regulatory
    Data” shall have the meaning given to it in Clause 4.2 of this Agreement.
	 	 
	1.29	“Regulatory
    Documentation” means all (a) applications (including all INDs and Drug Approval Applications and other regulatory
    filings), registrations, licenses, authorizations, and approvals (including Regulatory Approvals); (b) correspondence and
    reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any
    communications with any Regulatory Authority) and all supporting documents with respect thereto, including all regulatory
    drug lists, advertising and promotion documents, adverse event files, and complaint files; and (c) pre-clinical and clinical
    data, and data contained or relied upon in any of the foregoing, in each case (a), (b), and (c) relating to Product.
	 	 
	1.30	“Specifications”
    means all data necessary to manufacture the Product and contained in the most recent version of the product specification
    file, IMPD or IND.
	 	 
	1.31	“Territory”
    means all the countries of the European Union and Turkey.
	 	 
	1.32	“Trademark”
    means any word, name, symbol, color, designation or device or any combination thereof that functions as a source identifier,
    including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo, business symbol or domain names
    whether or not registered.

 

    	 6
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

2
– EAP activities & management

2.1
EAP Activities.

 

IMPATIENTS
shall perform EAP activities, including selling and distributing the Product in the Territory. IMPATIENTS shall use reasonable
commercial efforts to assure that all requested and relevant information is presented to regulatory authorities, decision makers,
patients and/or responsible medical specialists, including informing patients and health care practitioners in general about their
opportunities to apply for Early Access Approvals in the Territory.

 

2.2
Collaborative Committees.

 

As
soon as practical after the Effective Date, but no later than thirty (30) days thereafter, the Parties shall establish a joint
steering committee (the “Joint Steering Committee” or “JSC”), which shall (a) oversee the EAP plan for
the Product in the Territory, (b) resolve Disputes that may arise in any subcommittees formed by the JSC, (c) coordinate the Parties’
activities under this Agreement, including oversight of any subcommittees formed by the JSC, and (d) perform such other functions
as are set forth herein or as the Parties may mutually agree in writing, except where in conflict with any provision of this Agreement.
The details of the composition, operating procedures and responsibilities of the Collaborative Committees are described in Exhibit
2.

 

2.3
Packaging.

 

Subject
to the provision by HEMISPHERX of appropriately labeled and packaged Product and associated materials, IMPATIENTS shall ensure
that such amounts of the Product and its associated materials as are supplied and distributed under the EAP Program shall prominently
display the Product Trademark, together with the information that the Product is manufactured and supplied by HEMISPHERX.

 

3
– Grants of rights, disclosure of know how

 

3.1
Appointment.

 

	3.1.1	HEMISPHERX
    hereby appoints IMPATIENTS as its exclusive service provider to perform EAP activities for Product in the Field in the Territory.
	 	 
	3.1.2	HEMISPHERX
    hereby grants IMPATIENTS an exclusive, non-transferable, royalty-free right to reproduce and use the Product’s Trademarks
    solely in connection with performing the EAP activities for Product in the Field in the Territory, subject to the terms and
    conditions set forth herein, including in Exhibit 3.

 

3.2
IMPATIENTS Know How Contribution.

 

IMPATIENTS
undertakes to contribute its Know How to perform the EAP, including but not limited its EAP technical and business knowledge regarding
patient and physician outreach, regulatory and legal support, pharmacovigilance, reimbursement, data collection, logistics and
marketing.

 

    	 7
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

3.3
HEMISPHERX Know How Disclosure.

 

Immediately
after the Effective Date, HEMISPHERX shall collaborate with IMPATIENTS make available to IMPATIENTS, in whatever form IMPATIENTS
may reasonably request, Regulatory Documentation, HEMISPHERX Know How, and any other Information relating directly or indirectly
to the Product and reasonably required to implement and manage the EAP in the Territory (including, but not limited to, information
related to Manufacturing), to the extent not done so already, and thereafter immediately upon the availability of such Regulatory
Documentation, HEMISPHERX Know How, or other Information. For the avoidance of doubt, where necessary, HEMISPHERX will and shall
cause its Affiliates and collaborators, without additional compensation, to make available to IMPATIENTS relevant information
agreed upon with IMPATIENTS under this Clause 3.3.

 

3.4
HEMISPHERX Know How Assistance.

 

HEMISPHERX,
at its sole cost and expense, shall provide IMPATIENTS with reasonable assistance required in order to transfer to IMPATIENTS
the Regulatory Documentation, HEMISPHERX Know How and other Information required to be produced hereunder, in each case in a timely
manner. HEMISPHERX shall reasonably assist IMPATIENTS with respect to the implementation of the EAP for the Product.

 

4
- Regulatory matters

 

4.1
Regulatory Activities.

 

	4.1.1	IMPATIENTS
    shall have the sole and exclusive right to make contact with patients and physicians relating to the EAP of Product, and to
    file applications for Early Access Approvals therefor (including the setting of the overall regulatory strategy therefor),
    and to communicate with the Regulatory Authorities to secure Early Access Approvals for Product in the Territory. HEMISPHERX
    shall support IMPATIENTS as may be reasonably necessary in obtaining Early Access Approvals for the Product, and in the activities
    in support thereof, including providing necessary documents or other materials required by Applicable Law to obtain Early
    Access Approvals, in each case in accordance with the terms and conditions of this Agreement.

 

    	 8
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

	4.1.2	HEMISPHERX
    shall collaborate with IMPATIENTS to provide IMPATIENTS with (a) access to or copies of all material written or electronic
    correspondence (other than regulatory filings) relating to the development of Product in the Field received by HEMISPHERX
    or its Affiliates, collaborators or licensees from, or filed by HEMISPHERX or its Affiliates, collaborators or licensees with,
    the Regulatory Authorities, and (b) copies of all meeting minutes and summaries of all meetings, conferences, and discussions
    held by HEMISPHERX or its Affiliates, collaborators or licensees with the Regulatory Authorities relating to the development
    or commercialization of Product in the Field, including copies of all contact reports produced by HEMISPHERX or its Affiliates
    or licensees, in each case ((a) and (b)) within fifteen (15) Business Days of its receipt, forwarding or production of the
    foregoing, as applicable. If such written or electronic correspondence received from any such Regulatory Authority relates
    to the withdrawal, suspension, or revocation of a Regulatory Approval or Early Access Approval for Product in the Field, the
    prohibition or suspension of the supply of a Product in the Field, or the initiation of any investigation, review, or inquiry
    by such Regulatory Authority concerning the safety and quality of a Product in the Field, the notified Party shall notify
    the other Party and provide the other Party with copies of such written or electronic correspondence as soon as practicable.
	 	 
	4.1.3	HEMISPHERX
    shall, in accordance with the Quality Agreement, make every reasonable effort to notify IMPATIENTS promptly following its
    determination that any event, incident, or circumstance has occurred that may result in the need for a recall, market suspension,
    or market withdrawal of a Product in the Territory in the Field, and shall include in such notice the reasoning behind such
    determination, and any supporting facts. HEMISPHERX (or its licensee) shall have the right to make the final determination
    whether to voluntarily implement any such recall, market suspension, or market withdrawal in the Territory. If a Regulatory
    Authority in the Territory mandates a recall, market suspension, or market withdrawal, then HEMISPHERX (or its licensee) shall
    initiate such a recall, market suspension, or market withdrawal in compliance with Applicable Law. For all recalls, market
    suspensions or market withdrawals undertaken pursuant to this Section 4.1.3, HEMISPHERX or its licensee, whichever responsible
    for the recall, market suspension, or market withdrawal, shall be solely responsible for the execution thereof, and IMPATIENTS
    shall reasonably cooperate in all such recall efforts.

 

4.2
Regulatory Data.

 

Within
the Field, each Party shall promptly provide to the other Party copies of, or access to all non-clinical and clinical data, and
other information, results, and analyses with respect to any development activities that are carried out by on or behalf of or
otherwise controlled by such Party or any of its Affiliates, collaborators or licensees (collectively, “Regulatory Data”),
when such Regulatory Data becomes available. For the avoidance of doubt, the requirements under this Clause 4.2 shall include
that HEMISPHERX shall provide IMPATIENTS with copies of up-to-date versions of (a) the EU GMP certificate of the manufacturing
site, (b) if applicable, the Product’s GMP certificate, (c) the Manufacturer’s manufacturing license for the Product,
(d) Product stability data and certificate of analysis, together with all other Know How that IMPATIENTS is required to include,
or may need to include, in its Early Access Approval applications.

 

    	 9
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

4.3
Pharmacovigilance.

 

Parties
shall enter into a separate agreement related to the responsibility and performance of pharmacovigilance activities related to
the Product. This Pharmacovigilance Agreement is attached as Exhibit 6.

 

4.4
Compliance.

 

Each
Party shall perform or cause to be performed, any and all of its development activities, in good scientific manner and in compliance
with all Applicable Law.

 

4.5
Records.

 

	4.5.1	Each
    of HEMISPHERX and IMPATIENTS shall, and shall ensure that its third party providers shall, maintain records in sufficient
    detail and in good scientific manner appropriate for regulatory purposes, and in compliance with Applicable Law, which shall
    be complete and accurate and shall properly reflect all work done and results achieved in the performance of its activities.
    HEMISPHERX or IMPATIENTS shall and retain all such records, as the case may be, for at least three (3) years after termination
    of this Agreement, or for such longer period as may be required by Applicable Law.
	 	 
	4.5.2	Each
    Party shall have the right, during normal business hours and upon reasonable notice, to inspect and make copies of all records
    of the other Party that pertain to the subject matter of this Agreement and that are reasonably required by such Party, except,
    without limitation, for files that cannot be shared due to applicable privacy regulations or that are subject to the attorney-client
    privilege. The inspecting Party shall maintain such records and the information disclosed therein in accordance with the confidentiality
    clauses of Clause 9 of this Agreement.
	 	 
	4.5.3	Without
    prejudice to the provisions of Clause 2, the JSC shall determine what reports shall be generated to track the EAP activities,
    including the content and timing thereof.

 

5
– Exclusive distribution, supply and manufacture

 

5.1
Distribution.

 

HEMISPHERX
hereby appoints IMPATIENTS as its sole and exclusive distributor in respect of EAP use of Product for use in the Field in the
Territory, limited to EAP use of Product in accordance with Early Access Approvals.

 

5.2
Product Supply.

 

	5.2.1	HEMISPHERX
    undertakes and agrees to supply to IMPATIENTS on an exclusive basis, IMPATIENTS’ requirements of Product ordered in
    accordance with the terms of this Agreement, for distribution and sale in the Territory, limited to EAP use of Product in
    accordance with Early Access Approvals.
	 	 
	5.2.2	IMPATIENTS
    undertakes and agrees to
    obtain its requirements of Product for use in the Field from HEMISPHERX in accordance with the terms of this Agreement.

 

    	 10
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

5.3
Product Manufacturing.

 

5.3.1
Manufacturing.

 

HEMISPHERX
shall solely be responsible for the manufacturing, fill & finish, labeling and, if applicable, stockpiling of cGMP grade Product
in compliance with the Quality Agreement attached as Exhibit 5, and shall exert its reasonable commercial best efforts to provide
quantities of cGMP Product sufficient to meet the requirements of the EAP. If HEMISPHERX contracts the manufacturing and/or filling
and/or finishing and/or labeling and/or stockpiling of Product to a third party, such third party shall be considered a Manufacturer.
HEMISPHERX will ensure that all relevant obligations deriving from this Agreement (including the Quality Agreement) between Parties
are part of the contractual relationship between HEMISPHERX and any Manufacturer. HEMISPHERX shall provide all required documentation
to IMPATIENTS related to the manufacturing for purposes of furthering the activities of the EAP.

 

5.3.2
Interruption of Supply.

 

If
HEMISPHERX is unable to meet IMPATIENTS’ requirements for Product, HEMISPHERX will notify IMPATIENTS and the JSC will meet
as soon as possible to negotiate a possible resolution.

 

6
- Supply of Product and Invoicing

 

6.1
Notification of Requirements.

 

IMPATIENTS
shall notify HEMISPHERX of its estimated Product requirements for the following {***} months {***} days before the
start of {***} (“Rolling Forecast”). Said estimate shall not constitute a firm commitment by IMPATIENTS. HEMISPHERX
shall, within 10 business days of receipt of such Rolling Forecast, indicate to IMPATIENTS if it agrees to such Rolling Forecast.
The enrollment of patients into the EAP and the Rolling Forecast shall be mutually agreed between the Parties.

 

6.2
Available Stock.

 

HEMISPHERX
shall use its best efforts to ensure that sufficient quantities of Product for 6 months of treatment for all patients then enrolled
in the EAP are in stock at the warehouse of IMPATIENTS’s logistics service provider (“LSP”). In addition, HEMISPHERX
shall use reasonable commercial efforts to ensure that sufficient quantities of Product for the following six months projected
sales, based on the most recent Rolling Forecast, as agreed in accordance with Clause 6.1, are in stock at the warehouse of IMPATIENTS’
LSP. The legal ownership of the stock in the warehouse of IMPATIENTS’ LSP (further referred to as “Consignment Stock”)
shall remain with HEMISPHERX and will at no time be transferred to IMPATIENTS or the LSP. At the time of IMPATIENTS’ delivery
of the Product through its LSP to its clients, legal ownership of the Product will directly transfer from HEMISPHERX to the relevant
client of IMPATIENTS. Any costs related to the keeping Consignment Stock shall be at the expense of IMPATIENTS.

 

    	 11
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

6.3
Product Shipment.

 

HEMISPHERX
shall deliver the Product DDP (INCOTERMS 2010) at the Consignment Stock warehouse address of IMPATIENTS’ LSP. At the warehouse
of IMPATIENTS’ LSP, Product will be made ready for delivery to IMPATIENTS’ clients, in a manner controlled by IMPATIENTS
and in accordance with the Quality Agreement.

 

6.4
Shipment Authorization.

 

HEMISPHERX
hereby authorizes IMPATIENTS to order its LSP to use Product from the Consignment Stock for the fulfilling of orders from IMPATIENTS’
clients without further approval from HEMISPHERX. HEMISPHERX shall make sure the Consignment Stock is replenished in a timely
manner to comply with the stock level requirement as mentioned in Clause 6.2.

 

6.5
Invoice.

 

IMPATIENTS
shall notify HEMISPHERX at the beginning of {***} of all fulfilled Product orders and Net EAP Sales (in Euros (€))
of Product from the preceding {***}. HEMISPHERX shall send IMPATIENTS an invoice in Euros (€) for 65% of Net EAP Sales
in such {***} and IMPATIENTS shall pay the amount of such invoice to HEMISPHERX in Euros (€) within {***} days
of receipt.

 

6.6
Product Pricing.

 

The
Price of the Product is specified in Exhibit 4. Prices are stated excluding VAT or other taxes or levies.

 

7
– Compensation to IMPATIENTS for agreed services

 

7.1
Royalty Obligation.

 

	7.1.1.1	During
    the EAP, IMPATIENTS shall, to the extent permitted by Applicable Law, collect information and data, including but not limited
    to patient-reported outcomes, doctor-reported experiences and registry data, and shall provide support services useful for
    Marketing Authorization applications in the Territory. As a compensation for the collection of such information and data,
    and/or the performance of such services, HEMISPHERX will pay to IMPATIENTS a royalty as further provided in this Clause 7.1.
	 	 
	7.1.1.2	In
    the event that HEMISPHERX or any of its Affiliates receives Marketing Authorization in the Field for the Product in any country
    in the Territory, then HEMISPHERX shall pay IMPATIENTS (or its successors or assigns) a royalty of up to a maximum of {***}%
    of Net Sales of Product in the countries in the Territory for which Marketing Authorization is granted. In the event that
    fifty (50) or more patients are entered into the EAP, such royalty percentage shall be calculated in accordance with the following
    formula:

 

{***}

 

    	 12
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

Exhibit
7 sets out a number of worked examples for this calculation.

 

	7.1.2	Royalties
    payable in respect of Net Sales shall be payable on a country-by-country basis for a period starting from the receipt of Marketing
    Authorization and ending the date{***} years from the First Commercial Sale of such Product in such country.
	 	 
	7.1.3	HEMISPHERX
    shall not be entitled to assign, sell or dispose of its rights in respect of the Product in the Field to a third party (including
    granting a third party the right to file for a Marketing Authorization based on HEMISPHERX’s rights and know how) unless
    such third party undertakes in writing to IMPATIENTS to be bound by the provisions of this Clause 7 as if such third party
    were a party to this Clause 7 instead of HEMISPHERX. For the avoidance of doubt, by third party in this Clause 7 is meant
    any person or entity that is not a Party to this agreement, including any Affiliate of HEMISPHERX.
	 	 
	7.1.4	For
    the purposes of the calculation of the royalty payment under this Clause 7.1, Product Net Sales shall be reported, and royalties
    based on such Product Net Sales shall be paid, to IMPATIENTS within {***} after the end of each {***} during
    which Product has been sold. HEMISPHERX, its Affiliates, licensees, successors and/or assigns shall maintain accurate records
    of Product sales for a period of no less than seven years. Such records may be audited for accuracy once a year by an independent
    public accounting firm, acceptable to both Parties, which accounting firm would be allowed reasonable access at reasonable
    times to review all relevant records.

 

8
– Warranties and Undertakings, Liability and Indemnity

 

8.1
Mutual Representations and Warranties.

 

The
Parties represent and warrant and, where relevant, undertake to each other, as of the Effective Date, as follows:

 

8.1.1
Organization.

 

It
is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization,
and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.

 

8.1.2
Authorization.

 

The
execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly authorized
by all necessary corporate action, and do not violate (a) such Party’s charter documents, bylaws, articles of association
or other organizational documents, (b) any material respect, any agreement, instrument, or contractual obligation to which such
Party is bound, (c) any requirement of any Applicable Law, or (d) any order, writ, judgment, injunction, decree, determination,
or award of any court or governmental agency presently in effect applicable to such Party.

 

    	 13
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

8.1.3
Binding Agreement.

 

This
Agreement is a legal, valid, and binding obligation of such Party, enforceable against it in accordance with its terms and conditions,
subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights,
judicial principles affecting the availability of specific performance, and general principles of equity (whether enforceability
is considered a proceeding at law or equity).

 

8.1.4
No Inconsistent Obligation.

 

It
is not under any obligation, contractual or otherwise, to any person that conflicts with or is inconsistent in any material respect
with the terms of this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder.

 

8.2
Product Warranty and Undertaking.

 

HEMISPHERX
warrants and undertakes that all Product supplied to IMPATIENTS under this Agreement shall comply with the Specifications; be
manufactured, filled, finished, labeled and packed in GMP facilities and in accordance with the Quality Agreement and all Applicable
Laws; be free from contamination or adulteration; be adequately packed to withstand transportation. At the time of delivery, each
Product shall have no less than 9 (nine) months of the Product’s registered shelf life remaining.

 

8.3
Product Liability.

 

HEMISPHERX
represents and warrants to IMPATIENTS that HEMISPHERX is legally bound to retain responsibility and liability for the manufacture
of the Product at all times and undertakes that it shall maintain product and general liability insurance covering any loss, costs,
expenses, liability, actions, demands, claims or proceedings relating to the Product.

 

8.4
Indemnity.

 

Each
Party shall indemnify and hold the other Party harmless from any claims, suits, demands, judgments, actions, liabilities, (including
strict liability and infringement of a third party’s patent rights) expenses (including reasonable attorney’s fees)
and damages relating to the Product and caused directly or indirectly by any act or omission of the other Party and its officers,
directors, employees, subcontractors, agents or suppliers, or (in the case of HEMISPHERX only) the Manufacturer. This indemnity
shall not apply if any such liability, loss, damage, cost or expense is due to the gross negligence or default in performance
by the indemnified Party, its officers, directors, employees, subcontractors, agents or suppliers.

 

    	 14
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

8.5 Waiver
of consequential or punitive damages.

 

Save
as for intentional wrongdoing by a Party, neither Party, nor any of their respective directors, officers, employees or agents
shall have any liability towards the other Party, for any indirect or consequential damages claimed by the other Party, including,
but not limited to the loss of opportunity, loss of use, and/or loss of revenue or profit, in connection with or arising out of
this Agreement or breach thereof.

 

8.6
Insurance

 

Each
Party shall maintain at its own cost at all times during the term of this Agreement, policies of insurance in such amounts and
to cover such risks as are reasonable, prudent and/or potentially foreseeable hereunder. Maintenance of such insurance coverage
will not relieve a Party of any responsibility under this Agreement for damages in excess of insurance limits or otherwise.

 

9
- Confidentiality

 

	9.1	The
    Parties will continue to abide by the confidentiality agreement signed by both Parties dated 11 June 2015, provided that the
    term of the confidentiality agreement shall be extended as long as necessary so as not to expire before the expiration or
    termination of this Agreement. The terms of confidentiality respecting Information shall not impede the appropriate
    use thereof in IMPATIENTS’s submission of Information in Early Access Approvals applications with Regulatory Authorities,
    in HEMISPHERX’s submission of Information in Marketing Authorization Applications with Regulatory Authorities, or in
    execution of the EAP of Product according to the EAP Plan.
	 	 
	9.2	HEMISPHERX
    acknowledges that the EAP Plan involves the publication of safety and efficacy information relating to the Product, including
    HEMISPHERX Confidential Information included in the Regulatory Documentation, and the patient- and doctor-reported outcomes
    and registry data generated and collected during the performance of the EAP. Therefore, HEMISPHERX hereby consents to IMPATIENTS
    publishing such HEMISPHERX’s Confidential Information as is required in accordance with Applicable Laws.
	 	 
	9.3	HEMISPHERX
    and IMPATIENTS agree to use all Confidential Information received under this Agreement solely for the purpose set forth herein
    and agree not to otherwise interfere in the business of the other in any respect.

 

10
- Duration, termination

 

	10.1	This
    Agreement will become legally effective on the Effective Date and, unless earlier terminated pursuant to the terms hereof,
    shall continue in full force and effect for an initial period of 5 (five) years. This initial period may be extended upon
    mutual written agreement between the Parties and in the absence of a notice to the other Party (to be given with at least
    90 days notice) from a Party that it does not agree to the extension of this Agreement under this Clause 10.1, shall be extended
    each anniversary by 12 months until commercial availability of the Product in the Territory following receipt by HEMISPHERIX
    or one of its Affiliates of appropriate Marketing Authorization.

 

    	 15
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

	10.2	Subject
    to any mandatory provision of law, this Agreement may be terminated by a Party, without any liability to the other, if the
    other Party is dissolved or liquidated, files or has filed against it a petition under any applicable bankruptcy or insolvency
    law, makes a general assignment for the benefit of its creditors, or has a receiver appointed for substantially all of its
    assets.
	 	 
	10.3	Following
    expiry of the initial 5-year term as set out in Clause 10.1, either Party may terminate this Agreement, provided the non-terminating
    Party is provided with 6 (six) months written notification.
	 	 
	10.4	HEMISPHERX
    shall have the right to terminate this agreement at any time during the Term provided that it shall provide IMPATIENTS with
    ninety (90) days written notification.
	 	 
	10.5	In
    the event that HEMISPHERX does not provide notification of ability to supply the Product for the EAP under Clause 6.2 within
    twelve (12) months of the Effective Date, IMPATIENTS shall be entitled to terminate this Agreement with thirty (30) days written
    notification.
	 	 
	10.6	Each
    Party reserves the right to immediately terminate this Agreement if the other Party is in breach of its material obligations
    under this Agreement and fails to remedy such breach within 6 (six) months written notification by the other Party of said
    breach. In the event of a breach not being capable of remedy within 6 (six) months of written notification, the parties shall
    negotiate in good faith to agree a period for remedy after which, if the breach remains, the Party whose obligations are not
    in such continuing breach shall be entitled to terminate this Agreement.

 

10.7
Consequences of Termination.

 

	10.7.1	In
    the event of a termination of this Agreement under Clauses 10.1 to 10.5 (inclusive), HEMISPHERX shall permit IMPATIENTS to
    continue to distribute and sell the Product until such time that the entire quantity of the Consignment Stock has been sold.
	 	 
	10.7.2	In
    the event of termination of this Agreement pursuant to Clause 10.1, termination by HEMISPHERX pursuant to Clause 10.3 or by
    IMPATIENTS pursuant to Clause 10.5, Clause 7.1 shall survive such termination and the royalty rate to be applied to Net Sales
    of Product shall be the percentage as calculated in accordance with such Clause 7.1, except that, for the purposes of the
    royalty calculation, the value of x shall be the higher of (a) 50 or (b) the cumulative number of patients that have entered
    the EAP for the Product under this Agreement.
	 	 
	10.7.3	In
    the event of termination of this Agreement by HEMISPHERX pursuant to Clause 10.4, Clause 7.1 shall survive such termination
    and the royalty rate to be applied to Net Sales of Product shall be set according to the Termination Algorithm outlined in
    Exhibit 7.
	 	 
	10.7.4	Upon
    termination of this Agreement by IMPATIENTS pursuant to Clause 10.3 or by HEMISPHERX pursuant to Clauses 10.5 or 10.6, Clause
    7.1 shall not survive termination and no royalty shall be payable to IMPATIENTS under such provision.

 

    	 16
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

10.8
Survival.

 

In
addition to and subject to the provisions of Clause 10.6, Clause 1, Clauses 4.5.1 and 4.5.2, Clause 6.5 and Clauses 8 to 11 shall
survive termination of this Agreement.

 

11
– Miscellaneous

 

11.1
Entire Agreement.

 

This
Agreement, together with the Confidentiality Agreement dated 11 June 2015 and signed by the Parties prior to the Effective Date,
constitutes the entire agreement between the Parties as regards the Product, and any former agreement relating to the same subject
matter hereby becomes null and void. In the event of any inconsistencies between the terms of these Agreements, the terms of this
Agreement shall prevail.

 

11.2
Amendments.

 

Modifications
to this Agreement shall be made in writing only, and shall only take effect when signed by both Parties.

 

11.3
Press releases

 

Each
Party shall have the right to disclose the existence of this Agreement, but not any of its material terms (which shall remain
Confidential Information of both Parties), provided that such disclosing Party shall provide to the other Party the proposed text
of any press release for review not less than five (5) days prior to public disclosure.

 

11.4
Independent Contractors.

 

It
is understood that both Parties hereto are independent contractors and engage in the operation of their own respective businesses.
Neither Party hereto is to be considered the agent of the other Party for any purpose whatsoever, and neither Party has any authority
to enter into any contract or assume any obligation for the other Party or to make any warranty or representation on behalf of
the other Party. Each Party shall be fully responsible for its own employees, servants and agents, and the employees, servants
and agents of one Party shall not be deemed to be employees, servants and agents of the other Party for any purpose whatsoever.

 

    	 17
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

11.5 Remedy;
Waiver.

 

Exercise
by any Party of any of its rights under this Agreement shall not be deemed to limit any other right or remedy that such Party
may have in law or equity. The waiver by either Party of a breach of any of the provisions of this Agreement by the other Party
shall not be construed as a waiver of any succeeding breach of the same or other provisions, nor shall any delay or omission by
either Party in exercising any right that it may have under this Agreement operate as a waiver of any breach or default by the
other Party.

 

11.6
Formalities.

 

Each
Party agrees to execute deliver and/or do such further papers, agreements or acts as may be necessary or desirable to give effect
to this Agreement and its purpose and to carry out its provisions.

 

11.7
Choice of Law and Dispute Resolution.

 

This
Agreement shall be governed by and interpreted under the laws of the Netherlands. All disputes arising out of or in connection
with this Agreement shall be submitted to the International Court of Arbitration of the International Chamber of Commerce and
shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by three arbitrators appointed
in accordance with the said Rules. Any such arbitration shall take place in Amsterdam, the Netherlands and in the English language.

 

11.8
Language.

 

This
Agreement is executed in the English language. The language used in this Agreement shall be deemed to be the language chosen by
the Parties hereto to express their mutual intent and no rule of strict construction against either Party shall apply to any term
or condition of this Agreement. The definitive language of this Agreement is English and no reliance shall be placed upon any
translation into any other language.

 

11.9
Assignment; Assumption.

 

Subject
to the provisions of Clause 7.1.3, neither this Agreement nor any rights or obligations hereunder may be assigned or duties delegated
(other than specified in the EAP Plan) by either Party without the prior written consent of the other Party, which consent shall
not be unreasonably withheld. Any assignment in violation of this clause shall be null and void. Any permitted assignee shall,
upon the request of the other Party hereto, expressly acknowledge, by written agreement, its assumption of all obligations and
liabilities under this Agreement.

 

11.10
Force Majeure.

 

Should
a Party be unable to perform any of its obligations under this Agreement due to an event of force majeure as determined by law
such Party shall be excused to perform its obligation during the period of such force majeure event provided always that it gives
the other Party prompt written notice of such force majeure event. If the event of force majeure were to prevent such Party performing
its obligations in connection with this Agreement for a continuous period of more than three (3) months, the other Party may terminate
the Agreement at its sole option by giving written notice thereof, without any indemnity to be paid by either Party. The termination
would then take effect without further notice, at the date of receipt of the above notice. In no event shall this provision relieve
either Party of its obligation to make payment when owing.

 

    	 18
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

11.11
Severability.

 

If
any provision of this Agreement is found to be invalid or unenforceable by any court or administrative body of competent jurisdiction,
then the invalidity or unenforceability of such provision shall not affect the other provisions of this Agreement, and all provisions
not affected by such invalidity or unenforceability shall remain in full force and effect. The Parties agree to attempt to substitute
for any invalid or unenforceable provision a valid or enforceable provision, which achieves to the greatest extent possible the
economic objectives of the invalid or unenforceable provision. If any provision of this Agreement conflicts with applicable legislation,
then the Parties shall modify such provision in order to comply with said legislation. This modification shall not affect the
other provisions of this Agreement.

 

11.12
Notice.

 

All
formal notices to be given pursuant to this Agreement shall be in writing and in English and shall be delivered by hand, sent
by registered mail return receipt, or by express courier service to the address of the Party to receive such notice as set out
below (or such other address as may be notified by a Party to the other from time to time). Notices shall be deemed to have been
received at the time of delivery by hand, at the date affixed on the return receipt or 3 (three) business days after sending if
sent by express courier service.

 

	 	For
    HEMISPHERX:	For
    IMPATIENTS:
	 	 	 
	 	HEMISPHERX:	Impatients
    N.V.:
	 	Attn:
    Thomas Equels	Attn.:
    {***}
	 	1617
    JFK Boulevard	Pilotenstraat
    45
	 	Suite
    500	1059
    CH
	 	Philadelphia,
    Pa. 19013	Amsterdam
	 	 	The
    Netherlands
	 	 	Email:
    {***}

 

11.13
Construction.

 

Except
where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of
any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Whenever
this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this
Agreement are for convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement
or the intent of any provision contained in this Agreement. The term “including,” “include,” or “includes”
as used herein shall mean “including, but not limited to,” and shall not limit the generality of any description preceding
such term. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict
construction shall be applied against either Party hereto. Each Party represents that it has been represented by legal counsel
in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying
the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such
terms and provisions.

 

    	 19
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement by their respective, duly authorized, representatives:

 

	 	For
    HEMISPHERX:	 	For
    IMPATIENTS:
	 	 	 	 
		s/Thomas
    Equels	 	s/Ronald
    Brus
	 	Thomas
    Equels	 	Ronald
    Brus
	 	CEO	 	CEO
    

 

    	 20
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

Exhibit
1. – EAP Plan

 

(to
be inserted after being agreed by JSC)

 

    	 21
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

Exhibit
2 – JSC and subcommittees

 

 

	1	JSC.
	 	
	1.1	Composition.
	 	 
	 	The
    JSC shall consist of{***}, each with the requisite experience and seniority to enable such person to make decisions
    on behalf of a Party with respect to the issues falling within the jurisdiction of the JSC. From time to time, each Party
    may substitute one or more of its representatives to the JSC on written notice to the other Party. {***}. The chairperson
    shall appoint a secretary of the Joint Steering Committee, who shall be {***}.
	 	 
	1.2	Specific
    Responsibilities.
	 	 
	 	The
    JSC shall oversee the EAP for the Product in the Territory, and shall serve as a forum for the coordination of activities
    for the Product for the Territory. In particular, the JSC shall:

 

	 	(a)	periodically
    (no less often than annually) review and serve as a forum for discussing the EAP, and review and approve amendments thereto;
	 	 	 
	 	(b)	oversee
    the conduct of EAP activities;
	 	 	 
	 	(c)	serve
    as a forum for discussing and coordinating strategies for obtaining Early Access Approvals and Regulatory Approvals for the
    Product in the Territory;
	 	 	 
	 	(d)	establish
    secure access methods (such as secure databases) for each Party to access Regulatory Documentation and other JSC related Information
    as contemplated under this Agreement; and
	 	 	 
	 	(e)	perform
    such other functions as are set forth herein or as the Parties may mutually agree in writing, except where in conflict with
    any provision of this Agreement.
	 	 	 
	 	(f)	Approve
    HEMISPHERX Know-How and Regulatory Documentation to be shared with Regulatory Authorities and physicians both under relevant
    confidentiality mechanisms.

 

	1.3	Disbandment.
	 	 
	 	Upon
    Marketing Authorization of the Product in all countries of the Territory, unless otherwise mutually agreed in writing, the
    JSC shall have no further responsibilities or authority under this Agreement and will be considered dissolved by the Parties.
	 	 
	1.4	Subcommittees.
	 	 
	 	From
    time to time, the JSC may establish and delegate duties to sub-committees or directed teams (“Subcommittees(s)”)
    on an “as-needed” basis to oversee particular projects or activities (for example, joint project team, joint finance
    group, and/or joint intellectual property group). Each such Subcommittee shall be constituted and shall operate as the JSC
    determines; provided that each Subcommittee shall have equal representation from each Party, unless otherwise mutually agreed.
    Subcommittees may be established on an ad hoc basis for purposes of a specific project or on such other basis as the
    JSC may determine. Each Subcommittee and its activities shall be subject to the oversight, review and approval of, and shall
    report to, the JSC. In no event shall the authority of the Subcommittee exceed that specified for the JSC. All decisions of
    a Subcommittee shall be by unanimous agreement.

 

    	 22
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

	2	General
    Provisions Applicable to committees.
	 	 
	2.1	Meetings
    and Minutes.
	 	 
	 	The
    committees shall meet quarterly by telephonic or tele video means, or, when necessary as agreed between the Parties, face-to-face,
    with the location of such face-to-face meetings alternating between locations designated by HEMISPHERX and locations designated
    by IMPATIENTS. The chairperson of the applicable committee shall be responsible for calling meetings on no less than thirty
    (30) Business Days’ notice. Each Party shall make all proposals for agenda items and shall provide all appropriate information
    with respect to such proposed items at least ten (10) Business Days in advance of the applicable meeting; provided
    that under exigent circumstances requiring input by the committee, a Party may provide its agenda items to the other Party
    within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular
    meeting, so long as the other Party consents to such later addition of such agenda items or the absence of a specific agenda
    for such meeting, such consent not to be unreasonably withheld or delayed. The chairperson of the committee shall prepare
    and circulate for review and approval of the Parties minutes of each meeting within thirty (30) days after the meeting. The
    Parties shall agree on the minutes of each meeting promptly, but in no event later than the next meeting of the committee.
    If the Parties cannot agree on the content of the minutes the objecting party shall append a notice of objection with the
    specific details of the objection to the proposed minutes.
	 	 
	2.2	Procedural
    Rules.
	 	 
	 	Each
    committee shall have the right to adopt such standing rules as shall be necessary for its work, to the extent that such rules
    are not inconsistent with this Agreement. A quorum of the committee shall exist whenever there is present at a meeting at
    least one (1) representative appointed by each Party. Representatives of the Parties on a committee may attend a meeting either
    in person or by telephone, video conference or similar means in which each participant can hear what is said by, and be heard
    by, the other participants. Representation by proxy shall be allowed. Each committee shall take action by unanimous agreement
    of the representatives present at a meeting at which a quorum exists, with each Party having a single vote irrespective of
    the number of representatives of such Party in attendance, or by a written resolution signed by at least one (1) representative
    appointed by each Party. Employees or consultants of either Party that are not representatives of the Parties on a Committee
    may attend meetings of such committee; provided, however, that such attendees (a) shall not vote or otherwise participate
    in the decision-making process of the Committee, and (b) are bound by obligations of confidentiality and non-disclosure equivalent
    to those set forth in Section 11.1 of the Agreement.

 

    	 23
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

	2.3	Committee
    Dispute Resolution.
	 	 
	 	If
    a subcommittee cannot, or does not, reach unanimous agreement on an issue at a meeting or within a period of ten (10) Business
    Days thereafter or such other period as the Parties may agree, then the dispute shall be referred to the JSC for resolution
    and a special meeting of the JSC may be called for such purpose. If the JSC cannot, or does not, reach unanimous agreement
    on an issue, including any dispute arising from the JSC, then the dispute shall first be referred to the senior officers of
    the Parties, who shall confer in good faith on the resolution of the issue. Any final decision mutually agreed to by the senior
    officers shall be conclusive and binding on the Parties.
	 	 
	2.4	Limitations
    on Authority.
	 	 
	 	Each
    Party shall retain the rights, powers, and discretion granted to it under this Agreement and no such rights, powers, or discretion
    shall be delegated to or vested in a committee unless such delegation or vesting of rights is expressly provided for in this
    Agreement or the Parties expressly so agree in writing. No committee shall have the power to amend, modify, or waive compliance
    with this Agreement, which may only be amended or modified as provided in Section 11.2 of the Agreement.
	 	 
	2.5	Alliance
    Manager.
	 	 
	 	Each
    Party shall appoint a person(s) who shall oversee contact between the Parties for all matters between meetings of each committee
    and shall have such other responsibilities as the Parties may agree in writing after the Effective Date (each, an “Alliance
    Manager”). Each Party may replace its Alliance Manager at any time by notice in writing to the other Party.
	 	 
	3	Discontinuation
    of Participation on a Committee.
	 	 
	 	Each
    committee shall continue to exist until the first to occur of: (i) the Parties mutually agreeing to disband the committee;
    or (ii) upon receipt of Marketing Authorization of the Product in the last country of the Territory.
	 	 
	4	Expenses.
	 	 
	 	Each
    Party shall be responsible for all travel and related costs and expenses for its members and other representatives to attend
    meetings of, and otherwise participate on, a committee.

 

    	 24
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

Exhibit
3 – Trademark usage conditions

 

1.
Product Trademark License Terms.

 

	 	1.1.	IMPATIENTS
    acknowledges HEMISPHERX’s exclusive right, title, and interest in and to the Product Trademarks and acknowledges that
    (i) neither this Agreement, nor its use of the Product Trademarks hereunder, shall be construed to accord to IMPATIENTS any
    rights in the Product Trademarks other than the limited license rights granted herein, and (ii) the goodwill generated thereby
    will inure solely and entirely to the benefit of HEMISPHERX.
	 	 	 
	 	1.2.	Should
    it be necessary to record IMPATIENTS as a registered licensee of the Product Trademarks in any jurisdiction, HEMISPHERX shall
    do so at IMPATIENTS’s expense, and IMPATIENTS will cooperate with HEMISPHERX to effect such recordation.

 

2.
Trademark Use.

 

	 	 	IMPATIENTS
    may use the Product Trademarks solely in conjunction with the Product EAP.
	 	 	 
	 	2.1.	Product
    Trademarks Usage Requirements.
	 	 	 
	 	 	IMPATIENTS
    agrees to comply with the Product Trademarks usage requirements of this Exhibit 2.1.
	 	 	 
	 	2.2.
    	The
    Product Trademarks may not be used in connection with the display, advertising, or promotion of Product for any purpose IMPATIENTS
    has not been appointed for.
	 	 	 
	 	2.3.
    	The
    Product Trademarks may not to be altered. The Product Trademarks are not to be used in conjunction with any other mark or
    design, i.e., the Product Trademarks must stand alone in terms of the commercial impression generated by the particular usage;
    provided, however, that IMPATIENTS’s trademarks may be used along with the Product Trademarks as long as such
    trademarks do not combine, superimpose or overlap with the Product Trademarks.
	 	 	 
	 	2.4.
    	IMPATIENTS
    must exercise care in the use of the Product Trademarks so as not to indicate to the public that IMPATIENTS is a division
    or affiliate of HEMISPHERX or otherwise related to HEMISPHERX.
	 	 	 
	 	2.5.	IMPATIENTS
    shall not use as its own trademark any word(s) or design(s) confusingly similar to the Product Trademarks.

 

3.
Protection of Interest.

 

If
IMPATIENTS becomes aware of any unauthorized use of the Product Trademarks by a third party, IMPATIENTS, subject to its confidentiality
obligations to other parties, agrees to promptly notify HEMISPHERX and to cooperate fully, at HEMISPHERX’s expense, in the
enforcement of HEMISPHERX’s rights against such a third party. Nothing contained in this Section shall be construed as to
require HEMISPHERX to enforce any rights against a third party or to restrict HEMISPHERX’s rights to license or consent
to such a third party’s use of the Product Trademarks.

 

    	 25
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

Exhibit
4 – Price of Product

 

Product
Price to be invoiced by IMPATIENTS to third parties (excluding VAT):

 

USD
{***} for a {***} course of treatment of {***} vials {***}. Meaning{***} vials in total, with
an equivalent price of USD {***} per vial

 

    	 26
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

Exhibit
5 - Quality Agreement

 

(to
be inserted after being agreed by JSC)

 

    	 27
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

Exhibit
6 -Pharmacovigilance Agreement

 

(to
be inserted after being agreed by JSC)

 

    	 28
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

Exhibit
7 –Royalty Payment Example Calculations

 

For
the purposes of illustration of the calculation of the royalty payments under Clause 7.1, the formula(s) would be calculated in
the following situations as follows:

 

{***}

 

This
demonstrates that if, during the course of the EAP, {***} patients have been admitted to the EAP the maximum royalty percentage
will have been reached.

 

In
the event of termination of this Agreement by HEMISPHERX pursuant to Clause 10.4, Clause 7.1 shall survive such termination and
the royalty rate to be applied to Net Sales of Product shall be set according to the following Termination Algorithm:

 

If
Hemispherx terminates without cause:

 

Royalty
Rate on Hemispherx Commerical Sales As a Function of EAP Performance and Time

 

	Cumulative EAP Patients	 	 >6 mos <1 year 	 	>1 yr <2 yrs 	 	>2 yrs <3yrs	 	>3 yrs <4 yrs 	 	>4 yrs <5 yrs	 

 

{***}

 

For
the avoidance of doubt, where the Termination Algorithm matrix above provides that, on termination by Hemispherx in accordance
with clause 10.4, the royalty rate shall be calculated in accordance with the formula, then such formula shall be the formula
set out in Clause 7.1, except that, for the purposes of the royalty calculation, the value of x shall be the higher of (a) {***}
or (b) the cumulative number of patients that have entered the EAP for the Product under this Agreement.

 

    	 29
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

Exhibit
8 –List of Deductions

 

Trade
discounts or rebates, mutually agreed between the Parties

 

Amounts
reserved for claims, allowances or credits connected with rejections or returns of Product

 

Packaging,
handling fees and costs of freight, insurance, sales taxes duties and other governmental charges (which sums shall include value
added tax and its equivalents, but shall not include income taxes)

 

    	 30
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

    	 

    

 

Exhibit
9 – Data to be collected

 

To
the extent permitted by Applicable Law, IMPATIENTS shall use it reasonable commercial efforts to collect the following data in
relation to the EAP:

 

	1)	Patient
    completed SF-36 questionnaire and Karnofsky Performance questionnaire every 8 weeks
	 	 
	2)	Physician’s
    Karnofsky performance score (based on patient questionnaire) every 8 weeks.
	 	 
	3)	Physician
    completed Chronic Fatigue Syndrome questionnaire
	 	 
	4)	Safety
    / adverse events in accordance with the Pharmacovigilance Agreement

 

    	 31
	{***} Confidential portions of this exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]